Alluvi, previously BI 4744, represents a promising advance in obesity care. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates remarkable effectiveness in https://mirrorbookmarks.com/story22042773/alluvi-a-comprehensive-investigation-into-the-retatrutide-s-prospects